Skip to main content Accessibility help
Hostname: page-component-684899dbb8-662rr Total loading time: 0.628 Render date: 2022-05-27T12:45:13.246Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Book contents

14 - Management of cancer of the liver, gallbladder and biliary tract

Published online by Cambridge University Press:  05 November 2015

Emma Harrett
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Seema Safia Arif
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Somnath Mukherjee
Oxford Cancer Centre, Oxford, UK
Louise Hanna
Velindre Cancer Centre, Velindre Hospital, Cardiff
Tom Crosby
Velindre Cancer Centre, Velindre Hospital, Cardiff
Fergus Macbeth
Velindre Cancer Centre, Velindre Hospital, Cardiff
Get access



Primary liver cancer is one of the commonest cancers worldwide, and it predominantly affects people in developing countries. It is often associated with chronic liver infections and it is more common in males. Patients usually present with advanced disease, and treatment options are influenced, and often limited, by comorbidities, especially poor function of the rest of the liver.

Tumours of the gallbladder and biliary tract are relatively rare. Patients often present late with symptoms of biliary obstruction, which, together with cholangitis, is a common cause of morbidity and death and the main target for palliative therapies. Gallbladder and biliary tract tumours are moderately chemosensitive. Cytological or histological confirmation of disease is often difficult, and specialist multidisciplinary teams with expert radiologists and pathologists should be involved in the diagnosis and staging. Radical surgery should be carried out only by tertiary surgical teams, and patients should be managed, whenever possible, within clinical trials.

Tumours of the liver

Types of tumour affecting the liver are shown in Table 14.1.

Anatomy of the liver

The liver is divided into right and left lobes by the falciform ligament, but more importantly, in terms of surgical resection, a segmental division can be made and seen with imaging, which is based upon the relationship to the hepatic and portal veins. There are four segments in both the left and the right liver. The left liver consists of the caudate lobe (segment I), the lateral segments II and III (superior and inferior lateral, respectively, seen extending to the left surface on CT) and the medial segment IV. The division between the lateral and medial segments is the gall bladder and IVC and not the falciform ligament. The right part of the liver is made up anteriorly of segments V and VIII (inferior and superior, respectively) and posteriorly of segments VI and VII (inferior and superiorly, respectively). The latter is the right lateral surface as seen on CT scan. Contrast in the portal, hepatic and inferior caval veins on CT allows distinct segmental definition.

Hepatocellular carcinoma

Incidence and epidemiology

Primary hepatocellular carcinoma (HCC) is the sixth most common solid tumour worldwide. Although the incidence is low in the UK and other developed countries, it is rising because of the increase in viral hepatitis.

Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


Aitken, K. L and Hawkins, M. A. (2014). The role of radiotherapy and chemoradiation in the management of primary liver tumours. Clin. Oncol. (R. Coll. Radiolol.), 26, 569–580.Google ScholarPubMed
Anderson, C. A., Rice, M., Pinson, C. al. (2004). FDG PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J. Gastrointest. Surg., 8, 90–97.CrossRefGoogle ScholarPubMed
Bismuth, H. and Corlette, M. B. (1975). Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg. Gynecol. Obstet., 140, 170–178.Google ScholarPubMed
Bismuth, H., Majno, P. E. and Adam, R. (1999). Liver transplantation for hepatocellular carcinoma. Semin. Liver Dis., 19, 311–322.CrossRefGoogle ScholarPubMed
Bujold, A., Masey, C. A., Kim, J. J., et al. (2013). Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J. Clin. Oncol., 31, 1631–1637.CrossRefGoogle ScholarPubMed
Chamberlain, R. S. and Blumgart, L. H. (2000). Hilar cholangiocarcinoma: a review and commentary. Ann. Surg. Oncol., 7, 55–66.CrossRefGoogle ScholarPubMed
Chen, J. S., Lin, Y. C., Jan, Y. Y., et al. (2001). Mitomycin with weekly 24-h infusion of high dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. Anticancer Drugs, 12, 339–343.CrossRefGoogle ScholarPubMed
Cheng, A. L., Kang, Y.K., Chen, Z., et al. (2009). Efficacy and safety of sorafenib in patients in the Asia–Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol., 10, 25–34.CrossRefGoogle ScholarPubMed
Cho, J. Y., Paik, Y. H., Chang, Y. S., et al. (2005). Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer, 104, 2753–2758.CrossRefGoogle ScholarPubMed
Choi, B. O., Jang, H. S., Kang, K. M., et al. (2006). Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. Jpn. J. Clin. Oncol., 36, 154–158.CrossRefGoogle ScholarPubMed
Choi, C. W., Choi, I. K., Seo, J. H., et al. (2000). Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am. J. Clin. Oncol., 23, 425–428.CrossRefGoogle ScholarPubMed
Fong, Y., Sun, R. L., Jarnagin, W., et al. (1999). An analysis of 412 cases of hepatocellular carcinoma at the Western center. Ann. Surg., 229, 790–800.CrossRefGoogle ScholarPubMed
Forner, A., Llovet, J. M. and Bruix, J. (2012). Hepatocellular carcinoma. Lancet, 379, 1245–1255.CrossRefGoogle ScholarPubMed
Glimelius, B., Hoffman, K., Sjödén, P. O., et al. (1996). Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol., 7, 593–600.CrossRefGoogle ScholarPubMed
Hoffmann, R. T., Paprottka, P. M., Schön, A., et al. (2011). Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc. Intervent. Radiol., 35, 105–106.Google ScholarPubMed
Khanna, V., Dhanasekaran, R., Barron, B. J., et al. (2009). Yttrium-90 radioembolization (SIR-Spheres) for cholangiocarcinoma: preliminary study. J. Vasc. Intervent. Radiol., 26 (2 Suppl.), S116–S117.Google Scholar
Kim, T. W., Chang, H. M., Kang, H. J., et al. (2003). Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann. Oncol., 14, 1115–1120.CrossRefGoogle ScholarPubMed
Kornek, G. V., Schuell, B., Laengle, F., et al. (2004). Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann. Oncol., 15, 478–483.CrossRefGoogle ScholarPubMed
Lamarca, A., Hubner, R. A., Ryder, W. D., et al. (2014). Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann. Oncol., 25, 2328–2338.CrossRefGoogle ScholarPubMed
Lau, W. Y., Leung, W. T., Ho, S., et al. (1994). Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br. J. Cancer, 70, 994–999.CrossRefGoogle ScholarPubMed
Lau, W. Y., Leung, T. W., Ho, S. K., et al. (1999). Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet, 353, 797–801.CrossRefGoogle ScholarPubMed
Lau, W. Y., Leung, W. T., Lai, B. S., et al. (2001). Pre-operative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann. Surg., 233, 236–241.CrossRefGoogle Scholar
Lee, J., Park, S. H., Chang, H. M., et al. (2012). Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol., 13, 181–188.CrossRefGoogle ScholarPubMed
Leung, T. W. T., Patt, Y. Z., Lau, W. Y., et al. (1999). Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin. Cancer Res., 5, 1676–1681.Google ScholarPubMed
Llovet, J. M. and Bruix, J. (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology, 37, 429–442.CrossRefGoogle ScholarPubMed
Llovet, J. M., Furster, J. and Bruix, J. (1999). Intention to treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology, 30, 1434–1440.CrossRefGoogle ScholarPubMed
Llovet, J. M.Ricci, S., Mazzaferro, V., et al. (2008). Sorafenib in advanced hepatocellualr carcinoma. N. Engl. J. Med.,. 359, 378–390.CrossRefGoogle Scholar
Lozano, R. D., Patt, Y. Z., Hassan, M. M., et al. (2000). Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer). Proc. Am. Soc. Clin. Oncol., 19, abstr. 1025.Google Scholar
Maindrault-Goebel, F., Selle, F., Rosmorduc, O., et al. (2003). A phase II study of gemcitabine and oxaliplatin (GEMOX) in advanced biliary adenocarcinoma (ABA). Final Results. Proc. Am. Soc. Clin. Oncol., 22, abstr. 1178.Google Scholar
Malka, D., Cervera, P., Foulon, S., et al. (2014). Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 15, 819–828.CrossRefGoogle ScholarPubMed
Mazzaferro, V., Regalia, E., Doci, R., et al. (1996). Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med., 334, 693–699.CrossRefGoogle ScholarPubMed
Mitry, E., van Custem, E., Van Laethem, J., et al. (2002). A randomised phase II trial of weekly high-dose 5FU with and without folinic acid and cisplatin in patients with advanced biliary tract adenocarcinoma: the EORTC 40955 trial. Proc. Am. Soc. Clin. Oncol., 21, abstr. 696.Google Scholar
Mornex, F., Girard, N., Beziat, C., et al. (2006). Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies – mature results of the French Phase II RTF-1 trial. Int. J. Radiat. Oncol. Biol. Phys., 66, 1152–1158.CrossRefGoogle ScholarPubMed
Muto, Y., Moriwaki, H., Ninomiya, M., et al. (1996). Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med., 334, 1561–1567.CrossRefGoogle ScholarPubMed
Nakagohri, T., Asano, T., Kinoshita, H., et al. (2003). Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J. Surg., 27, 289–293.CrossRefGoogle ScholarPubMed
Neoptolemos, J. P., Moore, M. J., Cox, T. F., et al. (2012). Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. J. Am. Med. Ass., 308, 147–156.CrossRefGoogle ScholarPubMed
NICE. (2013). Selective Internal Radiotherapy for Primary Hepatocellular Carcinoma, IPG460. London: National Institute for Health and Care Excellence.
O'Reilly, E. M., Stuart, K. E., Sanz-Altamira, P. M., et al. (2001). A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer, 91, 101–105.3.0.CO;2-K>CrossRefGoogle ScholarPubMed
Okusaka, T., Nakachi, K., Fukutomi, A., et al. (2010). Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br. J. Cancer, 103, 469–474.CrossRefGoogle ScholarPubMed
Oliveri, R. S., Wetterslev, J. and Gluud, C. (2011). Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.: CD004787.CrossRefGoogle ScholarPubMed
Ortner, M. E., Caca, K., Berr, F., et al. (2003). Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology, 125, 1355–1363.CrossRefGoogle ScholarPubMed
Pereira, S., Hughes, S. K., Roughton, M., et al. (2010). Photostent-02; Porfimer Sodium photodynamic therapy plus stenting versus stenting alone in patients (pts) with advanced or metastatic cholangiocarcinomas and other biliary tract tumours (BTC): A multicentre, randomised phase III trial. ESMO Congress 2010, Abstract no: 4580.Google Scholar
Philip, P. A., Mahoney, M., Thomas, J., et al. (2004). Phase II trial of erlotinib (OSI-774) in patients with hepatocelular or biliary cancer. Proc. Am. Soc. Clin. Oncol., 22 (no. 14S July 15 suppl.), 4025.CrossRefGoogle Scholar
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., et al. (1973). Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg., 60, 646–649.CrossRefGoogle ScholarPubMed
Rafi, S., Piduru, S. M., El-Rayes, B., et al. (2011). Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy and safety study. J. Vasc. Intervent. Radiol., 22 (3 Suppl), S89.CrossRefGoogle Scholar
SABR UK Consortium. (2015). Stereotactic Ablative Body Radiation Therapy (SABR): A Resource. Version 5.0. January 2015. Available at (accessed October 2015).
Saxena, A., Bester, L., Chua, T. C.,et al. (2010). Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann. Surg. Oncol., 17, 484–491.CrossRefGoogle ScholarPubMed
Schwartz, J. D., Schwartz, M., Goldman, J., et al. (2004). Bevacizumab in hepatocellular carcinoma in patients without metastasis and without invasion of the portal vein. Proc. Am. Soc. Clin. Oncol. (Post-Meeting edn.), 22 (14S July 15 suppl.), 4088.CrossRefGoogle Scholar
Seong, J., Keum, K. C., Han, K. H., et al. (1999). Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 43, 393–397.CrossRefGoogle ScholarPubMed
Sharma, A., Dwary, A. D., Mohanti, B. K., et al. (2010). Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J. Clin. Oncol., 28, 4581–4586.CrossRefGoogle ScholarPubMed
Takada, T., Amano, H., Yasuda, H., et al. (2002). Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer, 95, 1685–1695.Google ScholarPubMed
UICC. (2009). TNM Classification of Malignant Tumours. 7th edn. Eds. Sobin, L. H., Gospodarowicz, M. K., and Wittekind, Ch.. Chichester: Wiley-Blackwell.
Ursino, S., Greco, C., Cartei, F., et al. (2012). Radiotherapy and hepatocellular carcinoma: update and review of the literature. Eur. Rev. Med. Pharmacol. Sci., 16, 1599–1604.Google ScholarPubMed
Valle, J., Wasan, H., Palmer, D., et al. (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med., 362, 1273–1281.CrossRefGoogle ScholarPubMed
Verslype, C., Rosmorduc, O., Rougier, P., et al. (2012). Hepatocellular carcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 23(Suppl. 7), vii41–vii48.CrossRefGoogle ScholarPubMed
Weis, S., Franke, A., Mössner, J., et al. (2013). Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD003046.CrossRefGoogle ScholarPubMed
Yang, T. S., Lin, Y. C., Chen, J. S., et al. (2000). Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer, 89, 750–756.3.0.CO;2-R>CrossRefGoogle ScholarPubMed
Yeo, W., Mok, T. S., Zee, B., et al. (2005). A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl Cancer Inst., 97, 1532–1538.CrossRefGoogle ScholarPubMed
Yoshida, H., Tateishi, R., Arakawa, Y., et al. (2004). Benefits of interferon therapy in hepatocellular carinoma prevention for individual patients with chronic hepatitis C. Gut, 53, 425–430.CrossRefGoogle Scholar
Zoepf, T., Jakobs, R., Arnold, J. C., et al. (2005). Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am. J. Gastroenterol., 100, 2426–2430.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the or variations. ‘’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats